Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Expert Insights

Ignace Vergote, MD, PhD
Conference Coverage
Tisotumab Vedotin Improves Survival, Response Among Patients With Recurrent or Metastatic Cervical Cancer
11/08/2023

Featuring Ignace Vergote, MD, PhD

Featuring Ignace Vergote, MD, PhD ...
Ignace Vergote, MD, PhD, discusses results from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial.
Ignace Vergote, MD, PhD, discusses results from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial.
Ignace Vergote, MD, PhD,...
11/08/2023
Oncology
Berend van der Wilk, MD, Erasmus University Medical Center
Videos
Active Surveillance After Neoadjuvant Chemoradiation for Select Patients With Esophageal Cancer
11/07/2023

Featuring Berend van der Wilk, MD

Featuring Berend van der Wilk, MD ...
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Berend van der Wilk, MD, shares...
11/07/2023
Oncology
Elias Jabbour, MD, MD Anderson Cancer Center
Videos
Exploring Chemotherapy-Free Treatment for Patients With Philadelphia-Positive ALL
11/07/2023

Featuring Elias Jabbour, MD

Featuring Elias Jabbour, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Videos
Novel Advances in the Treatment of Patients With Myelofibrosis
11/07/2023

Featuring Ruben A. Mesa, MD, FACP

Featuring Ruben A. Mesa, MD, FACP ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Filippo Pietrantonio, MD, National Cancer Center Milan
Videos
Sotorasib Plus Panitumumab Improved PFS Among Patients With Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
11/07/2023

Featuring Filippo Pietrantonio, MD

Featuring Filippo Pietrantonio, MD ...
Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...
Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...
Primary results from the phase 3...
11/07/2023
Oncology
Jason Westin, MD
Videos
Selecting CAR T-Cell Therapy for Older Patients With Diffuse Large B-Cell Lymphoma
11/07/2023

Featuring Jason Westin, MD

Featuring Jason Westin, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jason Westin, MD, participated in a debate regarding choice of CAR T-cell therapy versus novel therapy for older adults with diffuse large B-cell lymphoma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jason Westin, MD, participated in a debate regarding choice of CAR T-cell therapy versus novel therapy for older adults with diffuse large B-cell lymphoma.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Christian Rolfo, MD, PhD
Conference Coverage
Tissue and Liquid Biopsies Effective for Detecting MET Exon 14 Skipping Mutations in NSCLC
11/06/2023

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
Christian Rolfo, MD, PhD, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, discusses results from the phase 2 VISION trial.
Christian Rolfo, MD, PhD, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, discusses results from the phase 2 VISION trial.
Christian Rolfo, MD, PhD, Icahn...
11/06/2023
Oncology
Expert Roundtable
Videos
Diagnosis and Risk Stratification of Mantle Cell Lymphoma: Part 1
11/03/2023

Featuring Kami Maddocks, MD, Jia Ruan, MD, PhD, and Krish Patel, MD

Featuring Kami Maddocks, MD, Jia Ruan...
In the first part of an expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD, on the diagnostics and risk stratification of mantle cell lymphoma.
In the first part of an expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD, on the diagnostics and risk stratification of mantle cell lymphoma.
In the first part of an expert...
11/03/2023
Oncology
Jia Ruan, MD, PhD
Videos
Long-Term Updates on Chemotherapy-Free Lenalidomide Plus Rituximab Treatment for MCL
11/03/2023

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
Jia Ruan, MD, PhD, shares 9-year follow-up findings from a phase 2 trial on the outcomes of chemotherapy-free lenalidomide plus rituximab combination therapy among patients with mantle cell lymphoma.
Jia Ruan, MD, PhD, shares 9-year follow-up findings from a phase 2 trial on the outcomes of chemotherapy-free lenalidomide plus rituximab combination therapy among patients with mantle cell lymphoma.
Jia Ruan, MD, PhD, shares 9-year...
11/03/2023
Oncology
Andrea Necchi, MD, San Raffaele Hospital
Videos
Intravesical Gemcitabine Delivery System, TAR-200, Shows Promise Among Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
11/03/2023

Featuring Andrea Necchi, MD

Featuring Andrea Necchi, MD
Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
Andrea Necchi, MD, describes the...
11/03/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement